161 related articles for article (PubMed ID: 36039426)
41. Cypripedin diminishes an epithelial-to-mesenchymal transition in non-small cell lung cancer cells through suppression of Akt/GSK-3β signalling.
Treesuwan S; Sritularak B; Chanvorachote P; Pongrakhananon V
Sci Rep; 2018 May; 8(1):8009. PubMed ID: 29789636
[TBL] [Abstract][Full Text] [Related]
42. Lung Cancer Stem Cells and Cancer Stem Cell-targeting Natural Compounds.
Maiuthed A; Chantarawong W; Chanvorachote P
Anticancer Res; 2018 Jul; 38(7):3797-3809. PubMed ID: 29970499
[TBL] [Abstract][Full Text] [Related]
43. Treatment with insulin-like growth factor 1 receptor inhibitor reverses hypoxia-induced epithelial-mesenchymal transition in non-small cell lung cancer.
Nurwidya F; Takahashi F; Kobayashi I; Murakami A; Kato M; Minakata K; Nara T; Hashimoto M; Yagishita S; Baskoro H; Hidayat M; Shimada N; Takahashi K
Biochem Biophys Res Commun; 2014 Dec; 455(3-4):332-8. PubMed ID: 25446090
[TBL] [Abstract][Full Text] [Related]
44. Emodin reduces Breast Cancer Lung Metastasis by suppressing Macrophage-induced Breast Cancer Cell Epithelial-mesenchymal transition and Cancer Stem Cell formation.
Liu Q; Hodge J; Wang J; Wang Y; Wang L; Singh U; Li Y; Yao Y; Wang D; Ai W; Nagarkatti P; Chen H; Xu P; Murphy EA; Fan D
Theranostics; 2020; 10(18):8365-8381. PubMed ID: 32724475
[TBL] [Abstract][Full Text] [Related]
45. LFG-500, a novel synthetic flavonoid, suppresses epithelial-mesenchymal transition in human lung adenocarcinoma cells by inhibiting NLRP3 in inflammatory microenvironment.
Yang D; Cao X; Wang F; Jiang H; Feng D; Guo H; Du L; Jin Y; Chen Y; Yin X; Li C
Cancer Lett; 2017 Aug; 400():137-148. PubMed ID: 28461245
[TBL] [Abstract][Full Text] [Related]
46. Sulforaphane inhibits epithelial-mesenchymal transition by activating extracellular signal-regulated kinase 5 in lung cancer cells.
Chen Y; Chen JQ; Ge MM; Zhang Q; Wang XQ; Zhu JY; Xie CF; Li XT; Zhong CY; Han HY
J Nutr Biochem; 2019 Oct; 72():108219. PubMed ID: 31473507
[TBL] [Abstract][Full Text] [Related]
47. Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states.
Yoshida T; Ozawa Y; Kimura T; Sato Y; Kuznetsov G; Xu S; Uesugi M; Agoulnik S; Taylor N; Funahashi Y; Matsui J
Br J Cancer; 2014 Mar; 110(6):1497-505. PubMed ID: 24569463
[TBL] [Abstract][Full Text] [Related]
48. IL-27 inhibits epithelial-mesenchymal transition and angiogenic factor production in a STAT1-dominant pathway in human non-small cell lung cancer.
Kachroo P; Lee MH; Zhang L; Baratelli F; Lee G; Srivastava MK; Wang G; Walser TC; Krysan K; Sharma S; Dubinett SM; Lee JM
J Exp Clin Cancer Res; 2013 Nov; 32(1):97. PubMed ID: 24274066
[TBL] [Abstract][Full Text] [Related]
49. Nannocystin Ax, a natural elongation factor 1α inhibitor from Nannocystis sp., suppresses epithelial-mesenchymal transition, adhesion and migration in lung cancer cells.
Sun C; Liu R; Xia M; Hou Y; Wang X; Lu JJ; Liu B; Chen X
Toxicol Appl Pharmacol; 2021 Jun; 420():115535. PubMed ID: 33848516
[TBL] [Abstract][Full Text] [Related]
50. Diverse pathways of epithelial mesenchymal transition related with cancer progression and metastasis and potential effects of endocrine disrupting chemicals on epithelial mesenchymal transition process.
Lee HM; Hwang KA; Choi KC
Mol Cell Endocrinol; 2017 Dec; 457():103-113. PubMed ID: 28042023
[TBL] [Abstract][Full Text] [Related]
51. Lung cancer and epithelial-mesenchymal transition.
Menju T; Date H
Gen Thorac Cardiovasc Surg; 2021 May; 69(5):781-789. PubMed ID: 33754237
[TBL] [Abstract][Full Text] [Related]
52. Prospects for new lung cancer treatments that target EMT signaling.
Otsuki Y; Saya H; Arima Y
Dev Dyn; 2018 Mar; 247(3):462-472. PubMed ID: 28960588
[TBL] [Abstract][Full Text] [Related]
53. Sanguinarine impedes metastasis and causes inversion of epithelial to mesenchymal transition in breast cancer.
Ghauri MA; Su Q; Ullah A; Wang J; Sarwar A; Wu Q; Zhang D; Zhang Y
Phytomedicine; 2021 Apr; 84():153500. PubMed ID: 33626427
[TBL] [Abstract][Full Text] [Related]
54. Honokiol inhibits EMT-mediated motility and migration of human non-small cell lung cancer cells in vitro by targeting c-FLIP.
Lv XQ; Qiao XR; Su L; Chen SZ
Acta Pharmacol Sin; 2016 Dec; 37(12):1574-1586. PubMed ID: 27593221
[TBL] [Abstract][Full Text] [Related]
55. ERK1/2 blockade prevents epithelial-mesenchymal transition in lung cancer cells and promotes their sensitivity to EGFR inhibition.
Buonato JM; Lazzara MJ
Cancer Res; 2014 Jan; 74(1):309-19. PubMed ID: 24108744
[TBL] [Abstract][Full Text] [Related]
56. Reduction of metastatic potential by inhibiting EGFR/Akt/p38/ERK signaling pathway and epithelial-mesenchymal transition after carbon ion exposure is potentiated by PARP-1 inhibition in non-small-cell lung cancer.
Chowdhury P; Dey P; Ghosh S; Sarma A; Ghosh U
BMC Cancer; 2019 Aug; 19(1):829. PubMed ID: 31438892
[TBL] [Abstract][Full Text] [Related]
57. Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors.
Bonde AK; Tischler V; Kumar S; Soltermann A; Schwendener RA
BMC Cancer; 2012 Jan; 12():35. PubMed ID: 22273460
[TBL] [Abstract][Full Text] [Related]
58. Triclosan potentiates epithelial-to-mesenchymal transition in anoikis-resistant human lung cancer cells.
Winitthana T; Lawanprasert S; Chanvorachote P
PLoS One; 2014; 9(10):e110851. PubMed ID: 25329306
[TBL] [Abstract][Full Text] [Related]
59. Narrower insight to SIRT1 role in cancer: A potential therapeutic target to control epithelial-mesenchymal transition in cancer cells.
Choupani J; Mansoori Derakhshan S; Bayat S; Alivand MR; Shekari Khaniani M
J Cell Physiol; 2018 Jun; 233(6):4443-4457. PubMed ID: 29194618
[TBL] [Abstract][Full Text] [Related]
60. Gli promotes tumor progression through regulating epithelial-mesenchymal transition in non-small-cell lung cancer.
Jiang L; Huang J; Hu Y; Lu P; Luo Q; Wang L
J Cardiothorac Surg; 2020 Jan; 15(1):18. PubMed ID: 31931858
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
